The 1983rd day of the spiral public number accompanies you in scientific research
The recovery of foreign scientific research funds is not so easy
Recently, some scholars have published an article pointing out that professor Patrick Legembre, an internationally renowned immunologist, has suspected many sci papers of academic misconduct, and today we will take a look.
The scholar Patrick Legembre was born in France in 1974, and in 2002, at the age of 28, he received his doctorate from the University of Bordeaux. During his Ph.D., he first discovered that the protein cd95 (also known as fas), a member of the TNF receptor family, can act as a regulator for immune tolerance and immune surveillance. From 2002 to 2005, after doing his Ph.D. in the laboratory of Professor Marcus Peter at the University of Chicago, he explored the function of CD95 and found that CD95 can promote cancer through a non-apoptotic way.
Perhaps obsessed with the protein CD95, patrick Legembre was introduced as principal investigator by the University of Bordeaux in France between 2005 and 2010. During this time, his research team found that in the process of anti-cancer drug treatment, CD95 re-migrated into lipid rafts, inhibiting tumorigenesis, elaborating on the contradictory role of CD95 in the development of tumorigenesis.
Since 2010, Patrick Legembre has been teaching at the University of Rennes in France. There, he revealed that CD95 affects the occurrence of a variety of diseases such as systemic lupus erythematosus as well as triple-negative breast cancer.
It can be seen that in more than 20 years of scientific research, Professor Patrick Legembre has been researching the key molecule cd95. Because of this dedication, he is a top expert in the field. A total of 64 professional papers have been published, with a total of more than 3,000 citations and an h-index of 25.
In addition to publishing many high-level papers, Professor Patrick Legembre is also actively promoting CD95 related theoretical research to clinical application, and has obtained 6 patents. For his contributions to basic research and translational citations, Professor Patrick Legembre was awarded the Anr Young Scientist Award.
As an outstanding young scientist, he has high hopes and has received research grants of up to 2.3 million euros, or about 18 million yuan, in recent years.
Although Professor Patrick Legembre has made outstanding contributions to the functional research and application of CD95, his research papers in this field have been repeatedly questioned for falsification in recent times.
The first paper was published in the journal Cancer Research in November 2013 with an impact factor of 8.378. The article, titled cd95l cell surface cleavage triggers a prometastatic signaling pathway in triple-negative breast cancer, has been cited 58 times.
For this paper, recent peer scholar Enypia Venata said that the figure 5d immunoblot picture and figure s5c and figure s5h immunofluorescence picture in the article were reused.
The second paper, published in the journal PNAS in 2011, had an impact factor of 9.58. The article, titled cd95 triggers orai1-mediated localized ca2+ entry, regulates recruitment of protein kinase c (pkc) β2, and prevents death-inducing signaling complex formation, has been cited 47 times.
For the paper, the same scholar Enypia Venata said that the western blot pictures in Figure 1e and Figure S1e in the article were reused.
The third paper, published in 2008 in the journal Molecular Cancer Research, had an impact factor of 4.484. The article, titled Localization of fas/cd95 into the lipid rafts on down-modulation of the phosphatidylinositol 3-kinase signaling pathway, has been cited 68 times.
For the paper, scholar Perotrochus Teramachii said that the western blot images in Figures 4a and 7a in the article were reused.
The fourth paper was published in the journal Cancer Research in January 2007 with an impact factor of 8.378. The article, titled dominant-negative fas mutation is reversed by down-expression of c-flip, has been cited 24 times.
For the paper, scholar pterostylis tanypoda said figure 4a in the article was reused with the western blot map in an article published by the author in 2003.
The fifth paper was published in the journal Embo in August 2004 with an impact factor of 11.227. The article, titled cd95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells, has been cited 304 times.
For the paper, scholar pterostylis tanypoda said that the pictures in Figure 2b and Figure 3d in the article were suspected of cropping.
The sixth paper was published in the journal Scientific Reports in August 2016 with an impact factor of 4.011. The cleaved fas ligand activates the na(+)/h(+) exchanger nhe1 through akt/rock1 to stimulate cell motility, which has been cited 9 times so far.
For the paper, scholar pterostylis tanypoda said figure 2a in the article reused the author's western blot image published in the journal Plos biology in 2011.
Although Professor Pterostylis Tanypoda has published several papers implicated in behaviors such as image reuse and cropping. But since journals and schools still need some time to investigate, no papers have been retracted at this time. Under such ironclad evidence, it is believed that Professor Ptrostylis Tanypoda's future scientific career will be difficult. This also warns us young scholars not to cut off our future for a moment.
—end—